enzastaurin has been researched along with Glioblastoma with Sarcomatous Component in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Butowski, N; Chang, SM; Clarke, J; Costa, BM; Costello, JF; Hristova-Kazmierski, M; Hsieh, E; Lamborn, KR; Nicol, SJ; Nicole, A; Parvataneni, R; Pieper, R; Polley, MY; Prados, MD; Reis, RM; Sneed, PK; Thornton, DE; Vandenberg, S | 1 |
1 trial(s) available for enzastaurin and Glioblastoma with Sarcomatous Component
| Article | Year |
|---|---|
Phase II and pharmacogenomics study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme and gliosarcoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Neoplasms; Case-Control Studies; Chemoradiotherapy; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Dacarbazine; DNA Methylation; DNA, Neoplasm; Female; Follow-Up Studies; Glioblastoma; Gliosarcoma; Humans; Immunoenzyme Techniques; Indoles; Male; Middle Aged; Neoplasm Staging; Pharmacogenetics; Polymerase Chain Reaction; Prospective Studies; Survival Rate; Temozolomide; Treatment Outcome; Young Adult | 2011 |